{"id":46529,"date":"2022-07-25T17:02:17","date_gmt":"2022-07-25T15:02:17","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/"},"modified":"2022-07-25T17:02:17","modified_gmt":"2022-07-25T15:02:17","slug":"lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/","title":{"rendered":"LFB Announces the Approval of CEVENFACTA\u00ae (eptacog beta) in the European Union"},"content":{"rendered":"<div>\n<p>\n<b>This new recombinant coagulation Factor VIIa is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in adults and adolescents (12 years of age or older) with haemophilia A or B with inhibitors.<\/b>\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220725005414\/en\/1522688\/5\/LFB-ETHICAL-COMMITMENT-Quadri.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220725005414\/en\/1522688\/21\/LFB-ETHICAL-COMMITMENT-Quadri.jpg\"><\/a><\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>The first new bypassing agent approved in the European Union for the treatment and control of bleeding episodes in haemophilia A and B patients with inhibitors in over 2 decades.<\/b>\n<\/li>\n<li>\n<b>This marketing authorization in the European Union follows the FDA approval in April 2020 of SEVENFACT<sup>\u00ae <\/sup>(another brand name of eptacog beta) in the United States for the treatment of bleeding episodes in adults and adolescents with haemophilia A or B with inhibitors.<\/b>\n<\/li>\n<li>\n<b>In addition to this marketing authorization in the United States and in the European Union, LFB has been granted a Marketing Authorization for SEVENFACT\u00ae in Mexico on June 2<sup>nd<\/sup>, 2022.<\/b>\n<\/li>\n<li>\n<b>The marketing authorization file has also been submitted to the UK authorities (MHRA) and the file is currently under review.<\/b>\n<\/li>\n<\/ul>\n<p>LES ULIS, France&#8211;(BUSINESS WIRE)&#8211;LFB today announced that the European Medicines Agency (EMA) has granted on July 15<sup>th<\/sup> a Marketing Authorisation for CEVENFACTA\u00ae (eptacog beta), as the first new bypassing agent in over 20 years. CEVENFACTA\u00ae is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nin patients with congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX (i.e. \u22655 Bethesda Units (BU));\n<\/li>\n<li>\nin patients with congenital haemophilia with low titre inhibitors (BU &lt;5), but expected to have a high anamnestic response to factor VIII or factor IX administration or expected to be refractory to increased dosing of FVIII or FIX.\n<\/li>\n<\/ul>\n<p>\n<b>Denis Delval, LFB\u2019s Chairman and Chief Executive Officer,<\/b> stated: \u201c<i>We are very pleased with the approval of CEVENFACTA<\/i><b><sup>\u00ae <\/sup><\/b><i>by the EMA, which provides a new treatment option for haemophilia patients with inhibitors in the European Union. This approval is a validation of our innovative LFB technology and<\/i> <i>the acknowledgement<\/i> <i>of LFB\u2019s deep commitment to patients.\u201d<\/i>\n<\/p>\n<p>\n<b>Dr. Patrick Delavault, MD, LFB\u2019s Executive Vice President Scientific, Medical and Regulatory Affairs,<\/b> stated: \u201c<i>We need to keep in mind constantly what a bleeding event, even a single bleeding event, means to a haemophilia patient with inhibitors and to his family. This novel treatment alternative is a significative opportunity to improve patients\u2019 lives\u201d.<\/i>\n<\/p>\n<p>\nLFB has been granted a Marketing Authorisation for SEVENFACT\u00ae (eptacog beta) in Mexico on June 2<sup>nd<\/sup> for the treatment of bleeding episodes in adults and adolescents with haemophilia A or B with inhibitors.\n<\/p>\n<p>\n<b>About PERSEPT studies:<\/b>\n<\/p>\n<p>\nThe approval of CEVENFACTA\u00ae was based on data from the phase III clinical trials, PERSEPT 1 and PERSEPT 3.\n<\/p>\n<p>\nThe <i>PERSEPT 1 Phase III<\/i>, multicentre, randomised, open-label crossover study of two initial dose regimens (75\u00b5g\/kg and 225\u00b5g\/kg), evaluated 468 bleeding episodes across the full type of severity of bleeding episodes (mild, moderate, and severe), in 27 adolescent and adult haemophilia A and B patients with inhibitors (12-54 years of age). Both dosing regimens met the primary endpoint with 81% and 90% of bleeds controlled at 12 hours with the 75\u00b5g\/kg dose and the 225\u00b5g\/kg dose respectively. By 24 hours, haemostatic efficacy (secondary endpoint) was retained in 96.7% of bleeding episodes treated with the 75 \u00b5g\/kg dose regimen and 99.5% of redundancy bleeding episodes treated with the 225 \u00b5g\/kg dose, without requiring any alternative therapy. The median time to attain haemostatic efficacy was 5.98 hours for the 75 \u00b5g\/kg dosing regimen and 3 hours for the 225 \u00b5g\/kg dosing regimen. A median of 2 injections was needed to treat a bleeding episode with the 75 \u00b5g\/kg and a median of only 1 injection of the 225 \u00b5g\/kg dosing regimen was needed.\n<\/p>\n<p>\nThe <i>PERSEPT 3 Phase III<\/i>, multicentre, open-label, single-arm study evaluated the safety and efficacy of CEVENFACTA\u00ae in haemophilia A or B patients with inhibitors who were scheduled for an elective surgical or other invasive procedure. 12 patients were enrolled in the study, 6 with minor procedures and 6 with major procedures. For major surgical\/invasive procedures, treatment was administered at an initial bolus dose of 200 \u00b5g\/kg immediately before the start of the invasive procedure. For a minor elective surgical procedure, an initial bolus dose of 75 \u00b5g\/kg was administered immediately before the start of the procedure. Overall, 81.8% of procedures were reported as successfully treated at 48 hours after the last administration of the product.\n<\/p>\n<p>\nNo thromboembolic events were reported in these two clinical trials. No Serious Adverse Events (SAEs) were considered as related to the treatment.\n<\/p>\n<p>\nPatients should be monitored for any signs of thrombosis, hypersensitivity and neutralising antibodies. The most frequently reported adverse reactions in studies were infusion site discomfort, infusion site haematoma, post-procedural haematoma, infusion related reaction, increased body temperature, dizziness and headache.\n<\/p>\n<p>\n<b><i>About LFB<\/i><\/b>\n<\/p>\n<p>\n<i>LFB is a bio-pharmaceutical group that develops, manufactures and markets plasma derived products and recombinant proteins for the treatment of patients with serious and often rare diseases. LFB was founded in 1994 in France and is among the leading European bio-pharmaceutical companies providing mainly hospital-based healthcare professionals with blood-derived therapeutics with the vision to provide treatment options to patients in three major areas: immunology, haemostasis, and intensive care.<\/i>\n<\/p>\n<p>\n<i>LFB currently markets 15 biomedicinal products in more than 30 countries.<\/i>\n<\/p>\n<p>\n<i>Please visit <\/i><span class=\"bwuline\"><i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.groupe-lfb.com&amp;esheet=52790039&amp;newsitemid=20220725005414&amp;lan=en-US&amp;anchor=www.groupe-lfb.com&amp;index=1&amp;md5=d8eef19e37c9946b030d70a0cbf3407b\" rel=\"nofollow noopener\" shape=\"rect\">www.groupe-lfb.com<\/a><\/i><\/span><i> for further information on LFB.<\/i>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b><span class=\"bwuline\">LFB Contact<\/span>:<\/b><br \/><b>Didier V\u00e9ron &#8211; Executive Vice President, Corporate Affairs<\/b><br \/>Tel: +33 (0)1.69.82.72.97 or +33 (0)6.08.56.76.54<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#108;&#116;o:&#x76;&#x65;&#x72;&#x6f;&#110;&#100;id&#x69;&#x65;&#x72;&#64;&#108;&#102;b&#46;&#x66;&#x72;\" rel=\"nofollow noopener\" shape=\"rect\">&#118;&#101;&#x72;o&#110;&#x64;&#x69;d&#105;&#x65;&#x72;&#64;&#108;&#x66;b&#46;&#x66;&#x72;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>This new recombinant coagulation Factor VIIa is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in adults and adolescents (12 years of age or older) with haemophilia A or B with inhibitors. The first new bypassing agent approved in the European Union for &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46529","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LFB Announces the Approval of CEVENFACTA\u00ae (eptacog beta) in the European Union - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LFB Announces the Approval of CEVENFACTA\u00ae (eptacog beta) in the European Union - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"This new recombinant coagulation Factor VIIa is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in adults and adolescents (12 years of age or older) with haemophilia A or B with inhibitors. The first new bypassing agent approved in the European Union for ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-25T15:02:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220725005414\/en\/1522688\/21\/LFB-ETHICAL-COMMITMENT-Quadri.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"LFB Announces the Approval of CEVENFACTA\u00ae (eptacog beta) in the European Union\",\"datePublished\":\"2022-07-25T15:02:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\\\/\"},\"wordCount\":905,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220725005414\\\/en\\\/1522688\\\/21\\\/LFB-ETHICAL-COMMITMENT-Quadri.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\\\/\",\"name\":\"LFB Announces the Approval of CEVENFACTA\u00ae (eptacog beta) in the European Union - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220725005414\\\/en\\\/1522688\\\/21\\\/LFB-ETHICAL-COMMITMENT-Quadri.jpg\",\"datePublished\":\"2022-07-25T15:02:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220725005414\\\/en\\\/1522688\\\/21\\\/LFB-ETHICAL-COMMITMENT-Quadri.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220725005414\\\/en\\\/1522688\\\/21\\\/LFB-ETHICAL-COMMITMENT-Quadri.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LFB Announces the Approval of CEVENFACTA\u00ae (eptacog beta) in the European Union\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LFB Announces the Approval of CEVENFACTA\u00ae (eptacog beta) in the European Union - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/","og_locale":"en_US","og_type":"article","og_title":"LFB Announces the Approval of CEVENFACTA\u00ae (eptacog beta) in the European Union - Pharma Trend","og_description":"This new recombinant coagulation Factor VIIa is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in adults and adolescents (12 years of age or older) with haemophilia A or B with inhibitors. The first new bypassing agent approved in the European Union for ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-25T15:02:17+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220725005414\/en\/1522688\/21\/LFB-ETHICAL-COMMITMENT-Quadri.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"LFB Announces the Approval of CEVENFACTA\u00ae (eptacog beta) in the European Union","datePublished":"2022-07-25T15:02:17+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/"},"wordCount":905,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220725005414\/en\/1522688\/21\/LFB-ETHICAL-COMMITMENT-Quadri.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/","url":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/","name":"LFB Announces the Approval of CEVENFACTA\u00ae (eptacog beta) in the European Union - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220725005414\/en\/1522688\/21\/LFB-ETHICAL-COMMITMENT-Quadri.jpg","datePublished":"2022-07-25T15:02:17+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220725005414\/en\/1522688\/21\/LFB-ETHICAL-COMMITMENT-Quadri.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220725005414\/en\/1522688\/21\/LFB-ETHICAL-COMMITMENT-Quadri.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"LFB Announces the Approval of CEVENFACTA\u00ae (eptacog beta) in the European Union"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46529"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46529\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}